TCGA-B6-A0I9-01A-11R-A034-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.290
- G2M_CHECKPOINT+0.280
- MTORC1_SIGNALING+0.280
- ANDROGEN_RESPONSE+0.260
- PROTEIN_SECRETION+0.250
- PI3K_AKT_MTOR_SIGNALING+0.240
- DNA_REPAIR+0.210
- MITOTIC_SPINDLE+0.180
- PEROXISOME+0.150
- UNFOLDED_PROTEIN_RESPONSE+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- HEDGEHOG_SIGNALING-0.370
- WNT_BETA_CATENIN_SIGNALING-0.360
- ANGIOGENESIS-0.320
- TNFA_SIGNALING_VIA_NFKB-0.290
- INFLAMMATORY_RESPONSE-0.280
- APICAL_JUNCTION-0.250
- IL2_STAT5_SIGNALING-0.240
- KRAS_SIGNALING_UP-0.240
- MYOGENESIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.872 |
| 2 | MDT-AP-3402 | Med | Medulloblastoma | 0.844 |
| 3 | R321 | — | — | 0.838 |
| 4 | TCGA-XF-AAML-01A-11R-A42T-07 | — | — | 0.833 |
| 5 | MNG880 | — | — | 0.830 |
| 6 | R6 | — | — | 0.830 |
| 7 | BSR_14_0066_A2_S94 | — | C | 0.830 |
| 8 | R135 | — | — | 0.828 |
| 9 | SRR5903554 | — | cohortA1 | 0.828 |
| 10 | SRR12202421 | — | — | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |